For decades, RAS proteins were considered nearly impossible to target with drugs. NCI-supported basic research and the RAS Initiative helped lay the groundwork for new RAS inhibitors that are now benefiting patients and advancing through clinical trials.

Cancer Grand Challenges brings together international, interdisciplinary teams to tackle problems no single scientist, institution, or country can solve alone. Learn how the NCI and Cancer Research UK partnership is advancing cancer biology, prevention, and treatment while training future leaders.

In recognition of Childhood Cancer Awareness Month, NCI's Dr. Brigitte Widemann discusses recent advances in treatment, shared data, artificial intelligence, research participation, and survivorship. She explains why sustained federal investment and partnerships with patients, families, advocates, and researchers are essential to continued progress.